PMD דינמיקת רווח למניה בשנה הנוכחית Psychemedics

Cannabis legalization risks and rapid tests are weighing on revenue, causing year-over-year EPS shifts to reflect current volatility. The -274.90 level indicates the status of the profit parameter. Psychemedics (PMD) bases its business foundation on leadership in high-precision hair analysis, while operational activities are strictly limited by FDA regulations regarding the disposal of biomaterials.

Stable subscriptions from Psychemedics (PMD) for laboratory tests provided to courts and corporations directly drive the dynamics of the annual EPS range. This indicator measures the percentage shift in earnings per share relative to the previous year, revealing the business's actual resilience to market shocks. While the positive trajectory confirms the effectiveness of the diversification strategy, the sharp growth requires a comparison with multiples to avoid overpaying for the asset.